S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:VCEL

Vericel - VCEL Stock Forecast, Price & News

$28.13
+1.05 (+3.88%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.15
$28.33
50-Day Range
$22.88
$32.54
52-Week Range
$22.42
$60.24
Volume
344,989 shs
Average Volume
380,826 shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.33

Vericel MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.7% Upside
$37.33 Price Target
Short Interest
Bearish
16.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of Vericel in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.23) to $0.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

1016th out of 1,135 stocks

Biological Products, Except Diagnostic Industry

166th out of 180 stocks

VCEL stock logo

About Vericel (NASDAQ:VCEL) Stock

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Vericel Stock Performance

Shares of Vericel stock traded up $1.05 on Friday, reaching $28.13. The company had a trading volume of 344,989 shares, compared to its average volume of 380,826. The firm's 50 day moving average price is $27.14 and its two-hundred day moving average price is $31.46. The firm has a market cap of $1.33 billion, a PE ratio of -78.14 and a beta of 1.98. Vericel has a 52-week low of $22.42 and a 52-week high of $60.24.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. BTIG Research reduced their target price on shares of Vericel from $45.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, July 18th. Truist Financial reduced their price target on shares of Vericel to $33.00 in a research note on Friday, July 22nd. One research analyst has rated the stock with a sell rating and three have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.33.

Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Stock News Headlines

Vericel (VCEL) Q2 2022 Earnings Call Transcript
Vericel Reports Second Quarter 2022 Financial Results
Vericel Q2 2022 Earnings Preview - Seeking Alpha
Vericel (NASDAQ:VCEL) PT Lowered to $33.00
Vericel (NASDAQ:VCEL) Price Target Cut to $34.00
See More Headlines
Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Company Calendar

Last Earnings
11/08/2021
Today
8/14/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCEL
Employees
281
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$37.33
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+32.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-7,470,000.00
Pretax Margin
-10.81%

Debt

Sales & Book Value

Annual Sales
$156.18 million
Book Value
$3.71 per share

Miscellaneous

Free Float
44,725,000
Market Cap
$1.33 billion
Optionable
Optionable
Beta
1.98

Social Links


Key Executives














VCEL Stock - Frequently Asked Questions

Should I buy or sell Vericel stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings
or view top-rated stocks.

What is Vericel's stock price forecast for 2022?

3 analysts have issued 1 year price targets for Vericel's shares. Their VCEL share price forecasts range from $33.00 to $45.00. On average, they anticipate the company's stock price to reach $37.33 in the next year. This suggests a possible upside of 32.7% from the stock's current price.
View analysts price targets for VCEL
or view top-rated stocks among Wall Street analysts.

How have VCEL shares performed in 2022?

Vericel's stock was trading at $39.30 on January 1st, 2022. Since then, VCEL shares have decreased by 28.4% and is now trading at $28.13.
View the best growth stocks for 2022 here
.

When is Vericel's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VCEL earnings forecast
.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.08. The biotechnology company earned $34.51 million during the quarter, compared to analyst estimates of $38.07 million. Vericel had a negative trailing twelve-month return on equity of 9.75% and a negative net margin of 10.60%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the business earned $0.08 EPS.

What guidance has Vericel issued on next quarter's earnings?

Vericel issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $178.00 million-$189.00 million, compared to the consensus revenue estimate of $182.20 million.

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by many different institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (3.62%), Allspring Global Investments Holdings LLC (2.03%), Loomis Sayles & Co. L P (1.74%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (1.61%), JPMorgan Chase & Co. (1.41%) and Northern Trust Corp (1.11%). Insiders that own company stock include Dominick Colangelo, Gerard J Michel, Jonathan Mark Hopper, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends
.

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $28.13.

How much money does Vericel make?

Vericel (NASDAQ:VCEL) has a market capitalization of $1.33 billion and generates $156.18 million in revenue each year. The biotechnology company earns $-7,470,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does Vericel have?

The company employs 281 workers across the globe.

When was Vericel founded?

Vericel was founded in 1989.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (800) 556-0311, via email at ir@vcel.com, or via fax at 617-588-5554.

This page (NASDAQ:VCEL) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.